



Cohort summaries

Cohort name	Principal Investigator	Infection/s	Sample size	Country	Reference
Askøy Campylobacter Outbreak Study (ASCOS)	Prof. Guri Rørtveit	Campylobacter gastroenteritis	749	Norway	https://doi.org/10.1007/s15010-021-01652-3
Auckland IM and Campylobacter gastroenteritis cohorts	Prof. Rona Moss-Morris	IM, Campylobacter gastroenteritis	246	UK	https://pubmed.ncbi.nlm.nih.gov/20663256/
Bergen Giardiasis cohort, Norway	Dr. Knut-Arne Wensaas	Giardiasis	1252	Norway	https://pubmed.ncbi.nlm.nih.gov/29378314/
CHIKGene - Rheumatism and chronic fatigue, the two facets of post-chikungunya disease: the CHIKGene cohort study on Reunion island	Dr. Patrick Gérardin	Chikungunya	609	Reunion	https://pubmed.ncbi.nlm.nih.gov/29486812/
Chronic Fatigue following Acute EBV Infection in Adolescents (CEBA)	Prof. Vegard Bruun Bratholm Wyller	IM	270	Norway	https://pubmed.ncbi.nlm.nih.gov/30261303/
Dubbo Infection Outcome Study (DIOS)	Prof. Andrew Lloyd	IM, Q fever, RRV	495	Australia	https://pubmed.ncbi.nlm.nih.gov/16950834/
Dutch Q fever study (IMPAQT)	Dr. Jeannine Hautvast	Q-fever	336	Netherlands	https://pubmed.ncbi.nlm.nih.gov/24468188/ https://pubmed.ncbi.nlm.nih.gov/25452036/
Long term effects of COVID-19 in adolescents (LoTECA)	Prof. Vegard Bruun Bratholm Wyller	SARS-COV-2	508	Norway	https://pubmed.ncbi.nlm.nih.gov/36995712/
LymeProspect study	Dr. Kees van den Wijngaard	Lyme disease	1178	Netherlands	https://pubmed.ncbi.nlm.nih.gov/34557833/ https://pubmed.ncbi.nlm.nih.gov/15295705/ https://pubmed.ncbi.nlm.nih.gov/11789721/ https://pubmed.ncbi.nlm.nih.gov/11458965/
Natural History of IM, Seattle	Dedra Buchwald	IM	150	USA	https://pubmed.ncbi.nlm.nih.gov/11789721/ https://pubmed.ncbi.nlm.nih.gov/11458965/
Patient-reported outcomes and thromboembolism after COVID-19 without hospitalization (PROTROM)	Prof. Knut Stavem	SARS-COV-2	458	Norway	https://pubmed.ncbi.nlm.nih.gov/34028814/
Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2. (LongCOVID-study)	Dr. Tessa van der Maaden	SARS-COV-2	15,000	Netherlands	https://www.medrxiv.org/content/10.1101/2022.01.10.22269009v1
Prospective Study CFS following IM	Prof. Renee Taylor	IM	301	USA	https://pubmed.ncbi.nlm.nih.gov/19564299/
Prospective Study of the Natural History of IM Caused by EBV	Prof. Dedra Buchwald	IM	150	USA	https://pubmed.ncbi.nlm.nih.gov/11063953/
Qure Study. Treatment of Q-fever fatigue syndrome with CBT vs doxycycline vs placebo	Dr. Stephan Keijmel	Q-fever	155	Netherlands	https://pubmed.ncbi.nlm.nih.gov/28329131/ https://pubmed.ncbi.nlm.nih.gov/30654996/
ReCOVer - internet-based Cognitive Behavioural Therapy [iCBT] for severe fatigue after COVID-19	Prof. Hans Knoop	SARS-COV-2	114	Netherlands	https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad257/7157021
RECOVERED study - Evolution of COVID-19 symptoms during the first 12 months after illness onset	Prof. Maria Prins	SARS-COV-2	349	Netherlands	https://pubmed.ncbi.nlm.nih.gov/34473245/ https://pubmed.ncbi.nlm.nih.gov/35725782/ https://pubmed.ncbi.nlm.nih.gov/35415196/

The Post-hospitalization COVID-19 study (PHOSP)	Dr. Rachael Evans	SARS-COV-2	2235	UK	https://pubmed.ncbi.nlm.nih.gov/34627560/
Total sample size (N)			24,405		Last update: 8th of May 2023
IM - infectious mononucleosis; RRV – Ross River Virus; SARS-CoV-2 - Severe acute respiratory syndrome coronavirus 2.					